NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
(NCCN GUIDELINES®) RECOMMENDATIONS10*
Initial Systemic Therapy
Advanced or Metastatic Non–Small Cell Lung Cancer (mNSCLC)
- *For additional considerations and treatment options, see NCCN.org.
- a Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
- b EGFR, ALK, ROS1, BRAF negative or unknown, PD-L1 <50% or unknown, treatment option for patients with contraindications to the addition of pembrolizumab or atezolizumab.
- ALK=anaplastic lymphoma kinase; BRAF=B-Raf proto-oncogene; EGFR=epidermal growth factor receptor; NCCN=National Comprehensive Cancer Network;PD-L1=programmed death-ligand 1; PS=performance status; ROS1=c-ros oncogene 1.